Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab

BACKGROUND: Glioblastoma is one of the most aggressive and deadliest malignant tumors. Acquired resistance decreases the effectiveness of bevacizumab in glioblastoma treatment and thus increases the mortality rate in patients with glioblastoma. In this study, the potential targets of pentagamavunone...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermawan, Adam, Putri, Herwandhani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596150/
https://www.ncbi.nlm.nih.gov/pubmed/34819791
http://dx.doi.org/10.1016/j.jsps.2021.09.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596150/
https://www.ncbi.nlm.nih.gov/pubmed/34819791
http://dx.doi.org/10.1016/j.jsps.2021.09.015

Ejemplares similares